Axovant Sciences is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia, a condition characterized by significant decline in mental capacity and impaired daily function. Axovant’s goal is to be the leading global dementia solutions company, targeting this complex condition through multiple pharmacologic mechanisms of action.
Their lead drug candidate, RVT-101, will start a confirmatory phase 3 clinical study in mild-to-moderate Alzheimer's Disease patients in the fourth quarter of 2015. The drug has demonstrated statistically significant benefits in cognition and function in a 684-patient phase 2b study in patients with mild-to-moderate Alzheimer's disease. They also intend to develop RVT-101 for patients with other forms of dementia.